Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 7 | 2019 | 15 | 2.380 |
Why?
|
| Malpractice | 5 | 2015 | 10 | 1.600 |
Why?
|
| Prostatic Neoplasms | 8 | 2019 | 92 | 1.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 165 | 0.820 |
Why?
|
| Clinical Competence | 2 | 2015 | 207 | 0.800 |
Why?
|
| Prostate | 6 | 2019 | 31 | 0.720 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2012 | 33 | 0.650 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 75 | 0.630 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 9 | 0.630 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 5 | 0.630 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 44 | 0.620 |
Why?
|
| SEER Program | 4 | 2013 | 37 | 0.600 |
Why?
|
| Ureteroscopy | 1 | 2018 | 8 | 0.590 |
Why?
|
| Kidney Calculi | 1 | 2018 | 6 | 0.590 |
Why?
|
| Ureteral Calculi | 1 | 2018 | 6 | 0.590 |
Why?
|
| Simulation Training | 2 | 2019 | 36 | 0.570 |
Why?
|
| Stents | 1 | 2018 | 78 | 0.560 |
Why?
|
| Internship and Residency | 2 | 2018 | 208 | 0.550 |
Why?
|
| Models, Educational | 1 | 2017 | 23 | 0.550 |
Why?
|
| Nephrectomy | 3 | 2018 | 37 | 0.510 |
Why?
|
| Image-Guided Biopsy | 3 | 2019 | 34 | 0.440 |
Why?
|
| Prostatectomy | 4 | 2012 | 20 | 0.430 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.390 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 11 | 0.380 |
Why?
|
| Urologic Diseases | 1 | 2011 | 5 | 0.370 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 36 | 0.370 |
Why?
|
| Humans | 25 | 2019 | 25967 | 0.370 |
Why?
|
| Sarcoidosis | 1 | 2011 | 12 | 0.370 |
Why?
|
| Male | 19 | 2019 | 14277 | 0.350 |
Why?
|
| Marital Status | 1 | 2010 | 10 | 0.340 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.340 |
Why?
|
| Testicular Neoplasms | 1 | 2010 | 19 | 0.340 |
Why?
|
| Middle Aged | 14 | 2019 | 8772 | 0.320 |
Why?
|
| Penile Neoplasms | 1 | 2008 | 1 | 0.290 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 27 | 0.290 |
Why?
|
| Ultrasonography | 2 | 2019 | 207 | 0.260 |
Why?
|
| Postoperative Complications | 3 | 2018 | 901 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 117 | 0.250 |
Why?
|
| Liability, Legal | 1 | 2006 | 2 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 1059 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3358 | 0.250 |
Why?
|
| United States | 5 | 2015 | 1989 | 0.250 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 102 | 0.250 |
Why?
|
| Pneumothorax | 1 | 2005 | 11 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 135 | 0.230 |
Why?
|
| Female | 9 | 2019 | 14734 | 0.230 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 27 | 0.230 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 7 | 0.220 |
Why?
|
| Aged | 10 | 2018 | 8732 | 0.220 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 18 | 0.220 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 52 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 326 | 0.200 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.200 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 13 | 0.200 |
Why?
|
| Genital Neoplasms, Male | 1 | 2002 | 1 | 0.200 |
Why?
|
| Seminal Vesicles | 1 | 2002 | 2 | 0.200 |
Why?
|
| Rectum | 3 | 2018 | 50 | 0.200 |
Why?
|
| Glycoproteins | 1 | 2003 | 46 | 0.200 |
Why?
|
| Neurilemmoma | 1 | 2002 | 13 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 332 | 0.190 |
Why?
|
| Adult | 6 | 2018 | 7662 | 0.180 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 53 | 0.180 |
Why?
|
| Time Factors | 2 | 2017 | 1391 | 0.170 |
Why?
|
| Survival Rate | 2 | 2012 | 333 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 65 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 91 | 0.150 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 12 | 0.150 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 33 | 0.150 |
Why?
|
| Ovariectomy | 1 | 2018 | 26 | 0.150 |
Why?
|
| Hysterectomy | 1 | 2018 | 25 | 0.150 |
Why?
|
| Ureter | 1 | 2018 | 27 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 78 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2018 | 152 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 6 | 0.140 |
Why?
|
| Risk Factors | 3 | 2018 | 2237 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 28 | 0.140 |
Why?
|
| Renal Veins | 1 | 2017 | 2 | 0.140 |
Why?
|
| Surgical Stapling | 1 | 2017 | 4 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 102 | 0.140 |
Why?
|
| Renal Artery | 1 | 2017 | 6 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 85 | 0.130 |
Why?
|
| Self Report | 1 | 2017 | 217 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 140 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 367 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2017 | 185 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 2 | 2005 | 15 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1757 | 0.110 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 20 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 543 | 0.100 |
Why?
|
| Melanoma | 1 | 2013 | 49 | 0.100 |
Why?
|
| Comorbidity | 3 | 2018 | 476 | 0.100 |
Why?
|
| Kidney | 1 | 2013 | 147 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2012 | 32 | 0.100 |
Why?
|
| Genital Diseases, Male | 1 | 2011 | 6 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 258 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 297 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 70 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2010 | 23 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 15 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 1941 | 0.080 |
Why?
|
| Prognosis | 2 | 2010 | 784 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 174 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 30 | 0.080 |
Why?
|
| Incidence | 3 | 2018 | 729 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 84 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 198 | 0.070 |
Why?
|
| Physical Examination | 2 | 2005 | 117 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4641 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 648 | 0.070 |
Why?
|
| Cystectomy | 1 | 2006 | 8 | 0.060 |
Why?
|
| Urination Disorders | 1 | 2005 | 7 | 0.060 |
Why?
|
| Auscultation | 1 | 2005 | 4 | 0.060 |
Why?
|
| Pleura | 1 | 2005 | 8 | 0.060 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 9 | 0.060 |
Why?
|
| Case Management | 1 | 2005 | 7 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 27 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2017 | 3399 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 35 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 196 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 66 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 21 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 36 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2004 | 18 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 473 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 368 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 4 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 307 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 174 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 337 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 1107 | 0.040 |
Why?
|
| Education | 1 | 2019 | 36 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 33 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 53 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 52 | 0.040 |
Why?
|
| Lung | 1 | 2018 | 157 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 83 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 390 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 360 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 11 | 0.030 |
Why?
|
| Ligation | 1 | 2017 | 37 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 325 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 252 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 85 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 240 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 603 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 8 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 13 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 20 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 63 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 466 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 757 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1701 | 0.010 |
Why?
|